Difference between revisions of "Chidamide (Epidaza)"
Jump to navigation
Jump to search
m |
|||
| Line 9: | Line 9: | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
*2021-06-23: Newly indicated for the treatment of relapsed or refractory [[adult T-cell leukemia-lymphoma]]. | *2021-06-23: Newly indicated for the treatment of relapsed or refractory [[adult T-cell leukemia-lymphoma]]. | ||
| + | *2021-11-25: new indication for the treatment of relapsed or refractory [[peripheral T-cell lymphoma]]. | ||
| + | |||
==Also known as== | ==Also known as== | ||
*'''Code names:''' CS055, HBI-8000 | *'''Code names:''' CS055, HBI-8000 | ||
Revision as of 19:23, 6 June 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable benzamide type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Tucidinostat selectively binds to and inhibits HDAC leading to an increase of acetylation levels of histone protein H3. This agent also inhibits the expression of signaling kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells.
Diseases for which it is used
History of changes in PMDA indication
- 2021-06-23: Newly indicated for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
- 2021-11-25: new indication for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Also known as
- Code names: CS055, HBI-8000
- Generic name: tucidinostat
- Brand name: Epidaza, Hiyasta